Zytokinbestimmung aus Glaskörperproben bei retinalen Gefäßerkrankungen-Reference-Cited by-同舟云学术

Zytokinbestimmung aus Glaskörperproben bei retinalen Gefäßerkrankungen

Published:2012-12-09 Issue:8 Volume:110 Page:746-754
ISSN:0941-293X
Container-title:Der Ophthalmologe
language:de
Short-container-title:Ophthalmologe

Author:

Pfister M.,Koch F.H.,Cinatl J.,Rothweiler F.,Schubert R.,Singh P.,Ackermann H.,Koss M.J.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

http://link.springer.com/content/pdf/10.1007/s00347-012-2719-4.pdf

Reference33 articles.

1. Jo N, Wu GS, Rao NA (2003) Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 44(9):4054–4060

2. Pe’er J et al (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105(3):412–416

3. Morgan E et al (2004) Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 110(3):252–266

4. Eickmeier O et al (2010) Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine 50(2):152–157

5. Maier R et al (2006) Application of multiplex cytometric bead array technology for the measurement of angiogenic factors in the vitreous. Mol Vis 12:1143–1147

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vitreous expression of cytokines and growth factors in patients with diabetic retinopathy—An investigation of their expression based on clinical diabetic retinopathy grade;PLOS ONE;2021-05-19

2. Higher Aqueous Levels of Resistin and Lipocalin-2 Indicated Worse Visual Improvement following anti-VEGF Therapy in Patients with Retinal Vein Occlusion;Current Eye Research;2020-11-05

3. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema;Graefe's Archive for Clinical and Experimental Ophthalmology;2017-02-25

4. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance;Diabetologia;2016-05-14

5. Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study);Eye;2015-01-30